HONG KONG , Aug. 29, 2025 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2025 (the "Reporting Period").

Revenue Growth : The Group achieved revenue of approximately RMB676.7 million during the Reporting Period, representing a year-on-year increase of approximately 3.7%.

Stable Profitability: Gross profit was approximately RMB497.8 million . Excluding certain non-recurring items [1] , net profit attributable to owners of the Company was approximately RMB238.5 million

See Full Page